uniQure Crecimiento futuro
Future controles de criterios 2/6
uniQure se prevé un crecimiento anual de los beneficios y los ingresos de 20.6% y 38.6%, respectivamente, mientras que el BPA aumentará de grow a 24.9%.
Información clave
18.9%
Tasa de crecimiento de los beneficios
23.0%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 21.1% |
| Tasa de crecimiento de los ingresos | 38.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 04 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03
uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18UniQure: Leading Gene Therapy Company
Nov 06These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24How We Are Playing UniQure
Oct 04Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?
Sep 19Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 131 | -175 | -154 | -109 | 9 |
| 12/31/2025 | 85 | -197 | -191 | -171 | 13 |
| 12/31/2024 | 60 | -219 | -212 | -174 | 13 |
| 12/31/2023 | 16 | -308 | -153 | -146 | N/A |
| 9/30/2023 | 112 | -228 | -161 | -151 | N/A |
| 6/30/2023 | 112 | -187 | -251 | -239 | N/A |
| 3/31/2023 | 110 | -157 | -214 | -198 | N/A |
| 12/31/2022 | 106 | -127 | -163 | -145 | N/A |
| 9/30/2022 | 61 | -125 | -154 | -137 | N/A |
| 6/30/2022 | 62 | -114 | -149 | -129 | N/A |
| 3/31/2022 | 525 | 324 | 286 | 304 | N/A |
| 12/31/2021 | 524 | 330 | 271 | 288 | N/A |
| 9/30/2021 | 500 | 321 | 281 | 298 | N/A |
| 6/30/2021 | 500 | 303 | 292 | 303 | N/A |
| 3/31/2021 | 38 | -139 | -154 | -143 | N/A |
| 12/31/2020 | 38 | -125 | -144 | -135 | N/A |
| 9/30/2020 | 6 | -166 | -132 | -124 | N/A |
| 6/30/2020 | 5 | -136 | -120 | -111 | N/A |
| 3/31/2020 | 6 | -124 | -114 | -105 | N/A |
| 12/31/2019 | 7 | -124 | -105 | -99 | N/A |
| 9/30/2019 | 6 | -105 | -96 | -91 | N/A |
| 6/30/2019 | 8 | -103 | -93 | -89 | N/A |
| 3/31/2019 | 9 | -92 | -86 | -81 | N/A |
| 12/31/2018 | 11 | -83 | -80 | -76 | N/A |
| 9/30/2018 | 12 | -90 | -81 | -76 | N/A |
| 6/30/2018 | 11 | -78 | -76 | -71 | N/A |
| 3/31/2018 | 13 | -78 | -78 | -74 | N/A |
| 12/31/2017 | 13 | -79 | -70 | -64 | N/A |
| 9/30/2017 | 20 | -67 | N/A | -62 | N/A |
| 6/30/2017 | 25 | -72 | N/A | -65 | N/A |
| 3/31/2017 | 24 | -71 | N/A | -68 | N/A |
| 12/31/2016 | 25 | -73 | N/A | -72 | N/A |
| 9/30/2016 | 20 | -76 | N/A | -81 | N/A |
| 6/30/2016 | 16 | -90 | N/A | -62 | N/A |
| 3/31/2016 | 14 | -90 | N/A | 5 | N/A |
| 12/31/2015 | 11 | -82 | N/A | 7 | N/A |
| 9/30/2015 | 8 | -76 | N/A | 22 | N/A |
| 6/30/2015 | 6 | -58 | N/A | 13 | N/A |
| 3/31/2015 | 5 | -45 | N/A | -35 | N/A |
| 12/31/2014 | 6 | -50 | N/A | -37 | N/A |
| 9/30/2014 | 5 | -41 | N/A | -29 | N/A |
| 6/30/2014 | 6 | -42 | N/A | -6 | N/A |
| 3/31/2014 | 6 | -41 | N/A | -7 | N/A |
| 12/31/2013 | 4 | -37 | N/A | -6 | N/A |
| 9/30/2013 | 3 | -33 | N/A | -1 | N/A |
| 6/30/2013 | 1 | -27 | N/A | -18 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: QURE se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: QURE se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: QURE se prevé que siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: QURESe prevé que los ingresos de la empresa (31.9% al año) crezcan más deprisa que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: QURESe prevé que los ingresos de la empresa (31.9% al año) crezcan más deprisa que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de QURE se prevé elevada dentro de 3 años.